DataMEDS AI Announces Non-Binding MOU for Health Lives Here Programme with Florida HMO
DataMEDS AI has signed a non-binding MOU with an unnamed Florida-based HMO to deploy its Health Lives Here app, with an initial focus on GLP-1 treatment management.
DataMEDS AI, Inc. (NASDAQ:MEDS) has announced a non-binding Memorandum of Understanding with a Florida-based health maintenance organisation to introduce its Health Lives Here mobile application to the HMO’s members. The HMO’s identity has not been disclosed at its request, and the arrangement remains subject to definitive agreements.
The proposed programme would initially support members taking GLP-1 receptor agonist medications, with a focus on obesity and diabetes populations. Health Lives Here is intended to provide access to telehealth, pharmacy and laboratory testing services.
DataMEDS says the programme aims to support medication adherence and improve Healthcare Effectiveness Data and Information Set measures and Centers for Medicare & Medicaid Services star ratings. The company also identifies reducing hospitalisations and adverse drug events among patients receiving GLP-1 therapy as objectives.
The HMO serves Medicare Advantage members, including Chronic Special Needs Plan and Dual Eligible Special Needs Plan beneficiaries. It expects to have between 25,000 and 30,000 members for 2027 after open enrollment closes on December 8, 2026.
NFL Alumni Health, which DataMEDS describes as a strategic marketing partner for Health Lives Here, expects to assist with member health engagement activities. DataMEDS has identified compliance with CMS Medicare marketing and communications requirements and Federal Trade Commission endorsement guidance as considerations for those activities.
Under the proposed arrangement, DataMEDS would receive revenue through a ‘per member per month’ model for use of Health Lives Here by HMO members. An additional GLP-1 receptor agonist drug patient management programme could provide another revenue stream.
The company also identifies possible opportunities involving pharmacy dispensing, diagnostic laboratory testing and medical food products. Corexa Pharmacy, DataMEDS’ retail pharmacy, is in-network with the HMO’s pharmacy benefits manager and Medicare. DataMEDS’ Helomics diagnostic laboratory is in-network with Medicare.
The companies expect to execute definitive agreements in the fourth quarter of 2026 and begin introducing the application to members in the first quarter of 2027. The MOU is non-binding and is subject to those definitive agreements.
DataMEDS has also identified uncertainties involving rollout timing, PMPM pricing, member uptake and engagement, programme results and NFL Alumni Health’s participation. Other risks cited by the company include regulatory compliance, possible additional revenue opportunities, related-party arrangements with Tollo Health, LLC, reliance on a single initial payer customer, competition, Nasdaq listing compliance, liquidity, capital resources and its ability to fund operations.
DataMEDS AI describes itself as a healthcare company integrating technology, pharmacy, pharmaceutical-adjacent and telemedicine operations through health information technology platforms. Health Lives Here incorporates the company’s EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform.
The company’s Corexa Health subsidiary provides pharmacy dispensing and related services, while DataMEDS also owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory based in Pittsburgh, Pennsylvania.
Gerald Commissiong, Interim Co-CEO of DataMEDS, said the proposed arrangement would give the company its first corporate customer and help it refine Health Lives Here for payors. His comments were part of the company’s announcement and were made in the context of its plans for the platform.
DataMEDS AI announced that it had signed a non-binding Memorandum of Understanding with an unnamed Florida-based health maintenance organisation (HMO) to deploy the Health Lives Here mobile application to members, initially focusing on people using GLP-1 receptor agonist medications. The MOU is subject to definitive agreements.
The HMO’s name has been withheld at its request. The HMO serves Medicare Advantage members, including Chronic Special Needs Plan (C-SNP) and Dual Eligible Special Needs Plan (D-SNP) beneficiaries.
DataMEDS AI announced the MOU on November 5, 2026. The HMO expects to have between 25,000 and 30,000 members for 2027 following open enrolment that closes on December 8, 2026.
The proposed programme would use the Health Lives Here app to support members on GLP-1 receptor agonist medications, with access to telehealth, pharmacy and laboratory testing services. It is initially focused on obesity and diabetes members.
The programme aims to improve medication adherence, Healthcare Effectiveness Data and Information Set (HEDIS) measures and Centers for Medicare & Medicaid Services (CMS) star ratings. It also aims to reduce hospitalisations and adverse drug events for patients on GLP-1 therapy, although these are forward-looking statements from the company.
The proposed programme would generate revenue through a ‘per member per month’ (PMPM) model for use of the Health Lives Here app by all HMO members, with additional revenue from an add-on GLP-1 receptor agonist drug patient management programme. The source also identifies possible additional revenue opportunities from pharmacy dispensing, diagnostic laboratory testing and medical food products.
DataMEDS AI’s retail pharmacy Corexa Pharmacy is in-network with the HMO’s pharmacy benefits manager and Medicare, while its diagnostic laboratory, Helomics, is in-network with Medicare. The company’s platforms include the EinsteinRx artificial intelligence platform and the PharmacyChain blockchain-enabled smart contracts platform.
NFL Alumni Health, described as a Health Lives Here strategic marketing partner, expects to support member health engagement efforts. The company’s forward-looking statements also identify the need for those activities to comply with CMS Medicare marketing and communications requirements and FTC endorsement guidance.
DataMEDS AI is a healthcare company focused on integrating technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through health information technology platforms. Its Health Lives Here application incorporates the EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform, while Corexa Health provides pharmacy dispensing and related services and DataMEDS also owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory.
Gerald Commissiong, Interim Co-CEO of DataMEDS AI, said HMOs represent a significant opportunity for the company and Health Lives Here. He said the agreement would allow DataMEDS AI to add its first corporate customer and fine-tune its offering for payors, while also stating that the framework could support implementation by payor groups to improve efficiency and facilitate member engagement.
The companies expect to execute definitive agreements in the fourth quarter of 2026 and begin rolling out the app to members in the first quarter of 2027. The MOU is non-binding and subject to those definitive agreements.
DataMEDS AI identifies uncertainties around the timing of the rollout, PMPM pricing, member uptake and engagement, programme outcomes, NFL Alumni Health’s participation, regulatory compliance, additional revenue opportunities and related-party arrangements with Tollo Health, LLC. The company also cites dependence on a single initial payer customer, competition, Nasdaq listing compliance, liquidity, capital resources and its ability to fund operations, and says actual results may differ materially from its forward-looking statements.
DataMEDS AI identifies its shares as trading on Nasdaq under the ticker symbol NASDAQ:MEDS.